Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia

  title={Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia},
  author={Joseph Paladino and Robert Fell},
  journal={Annals of Pharmacotherapy},
  pages={384 - 389}
OBJECTIVE: To determine if dual individualization of cefmenoxime dosing is cost-effective. DESIGN: Retrospective, pharrnacoeconomic decisionanalysis of two consecutively conductedprospective clinical studies. PATIENTS: Patientswithdocumentedgram-negative nosocomial pneumoniawere evaluated. Thirty-three patients received cefmenoximeat standarddosing and 28 patients received doses according to dual individualization methodology. MAIN OUTCOME MEASURE: Antibiotic and infection-related costs were… 
Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
  • J. Paladino
  • Medicine, Biology
    The Canadian journal of hospital pharmacy
  • 1995
A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus
Cost-Effectiveness Comparison of Cefepime and Ceftazidime Using Decision Analysis
A retrospective cost-effectiveness analysis, from the institutional perspective, was performed on the 1637 clinically evaluable patients who participated in randomised studies of cefepime versus ceftazidime and revealed that ceftrazidime would have to be 31 % more effective than cefEPime to change the economic decision.
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Gatifloxacin monotherapy for CAP patients requiring hospitalization is clinically effective and provides an economic advantage compared to the regimen of ceftriaxone with or without IV erythromycin IV with a switch to oral clarithromycin.
Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/Ureidopenicillin Combination Therapy
Sensitivity analyses revealed that monotherapy can be cost effective compared with combination therapy in many situations, and drug cost should not be a deciding factor when choosing antibacterial therapy for the treatment of febrile episodes in adult patients with neutropenia.
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
The mean hospital costs associated with ciprofloxacin-metronidazole were similar to those of piperacillin-tazobactam for the treatment of adults with complicated intra-abdominal infections and lower costs were documented for patients able to be switched to oral antibiotics and for patients with appendicitis.
Cost-Effectiveness of Abbreviating the Duration of Intravenous Antibacterial Therapy with Oral Fluoroquinolones
In this analysis, switch therapy was a cost-effective treatment with no demonstrated change in efficacy compared with standard IV therapy.
Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
In patients able to receive oral therapy, sequential IV to oral treatment with ciprofloxacin plus metronidazole was cost effective compared with full IV courses of cipronidzole or imipenem-cilastatin.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
Despite a higher per-dose purchase price, overall costs with azithromycin tended to be lower due to decreased duration of therapy, lower preparation and administration costs, and reduced hospital length of stay.
Cost Effectiveness of Azithromycin Versus Cefuroxime, with/without Erythromycin, in Hospitalized Patients with Community Acquired Pneumonia.
The cost-effectiveness of azithromycin monotherapy for hospitalized patients with community acquired pneumonia against the current practice of a second generation cephalosporin with/without erythromycin is assessed.


Role for dual individualization with cefmenoxime.
Cefmenoxime in the treatment of nosocomial pneumonias in critical care patients.
Cefmenoxime is a promising agent for treatment of susceptible pneumonias in critical care patients and persistence in patients with good clinical response was considered colonization rather than superinfection.
Evaluating the cost-effectiveness of treatment with third-generation cephalosporins.
  • H. E. Gladen
  • Medicine
    Diagnostic microbiology and infectious disease
  • 1992
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
It is concluded that 200 mg of intravenous ciprofloxacin every 12 hours is highly effective for bacteria with MICs less than 0.25 microgram/ml, but higher dosages may be required to eradicate organisms with higher MICs.
Pharmacoeconomics: therapeutic and economic considerations in treating the critically ill patient.
  • V. Crane
  • Medicine, Political Science
    DICP : the annals of pharmacotherapy
  • 1990
Pharmacists can use newer tools such as cost-effective analysis and clinical decision analysis to identify and utilize drug therapies that result in decreased complications and decreased length of hospital stay, as measured by decreased costs.
Guidelines for performing a pharmacoeconomic analysis.
The fundamentals of pharmacoeconomics are presented and the pharmacist undertaking a pharmacoeconomic evaluation has the greatest likelihood of obtaining valid and useful results.
Management of pneumonia in the prospective payment era. A need for more clinician and support service interaction.
It is essential that clinicians and support service directors develop guidelines for testing and antibiotic use and management under prospective payment to minimize inefficient and ineffective practices.
Cost comparison of intravenous antibiotic administration
  • R. Plumridge
  • Medicine, Political Science
    The Medical journal of Australia
  • 1990
Daily total cost to administer antibiotics is a more appropriate and accurate costing method for antibiotics and hospitals must acknowledge the need for innovative resource allocation methods which recognise this fact.